Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
652 Views
eMediNexus 07 January 2023
On Thursday, Graphite Bio (GRPH.O) announced the suspension of an early-to-mid-stage trial of its blood disease therapy due to a serious adverse event in the first patient dosed.
The patient required ongoing blood transfusions and experienced sustained low blood cell counts after receiving Graphite′s nula-cel therapy, which the firm says is probably connected to its medication. According to Graphite, patients have shown no signs of blood cancer, which they have reported to the U.S. Food and Drug Administration (FDA).
The FDA-designated "fast track" drug Nula-cel was being investigated as a potential therapy for sickle cell disease, which causes an inadequate supply of healthy blood cells because sickle-shaped red blood cells are produced instead of round ones.
(Source: https://www.reuters.com/business/healthcare-pharmaceuticals/graphite-bio-pauses-early-stage-blood-disease-therapy-trial-2023-01-05/ )
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
High 1-hour Plasma Glucose: Early Indicator of Type 2 Diabetes Risk..
Maintaining Liver Health to Optimize Glycemic Outcomes in Early Type 2.....
Antibiotic Prescribing Practices for Pediatric Acute Otitis Media..
Hidden Hazard of Indoor Pollution in COPD..
Recognizing Pitfalls of Point-of-Care Lung Ultrasound..
{{Article_Title}}..
HMPV in India: Seven Cases Reported across Four States..
West Bengal Commission Fines Divine Nursing Home Rs 10 Lakh for Medical Negligence..
India Reports First Human Metapneumovirus (HMPV) Cases in Karnataka..
Two-Year-Old Dies after Wrong Injection Administered by Private Compounder in Jaisalmer..
'Law of the Land' Paramount for Blinkit's Ambulance Services, Says PiyushGoyal..